

**Novacyt S.A.**  
("Novacyt", the "Company" or the "Group")

**Half-year trading update**

**Paris, France, and Manchester, UK - 29 July 2025** -Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited trading update for the six months ended 30 June 2025.

**Financial Highlights**

- Unaudited Group statutory revenue for H1 2025 expected to be circa £9.8 million (H1 2024: £10.0 million - restated to remove any IT-IS International revenue due to its treatment under IFRS 5)
  - The underlying Group revenue has grown by circa 2% (4% on a constant currency basis), excluding the impact of the Taiwan service laboratory divestment
- Encouraging growth delivered by the Company's clinical segment, generating sales of £6.9 million
- NIPT technologies up over 10% year-on-year to £2.4 million
- Geographically, the APAC region achieved year-on-year growth of circa 9%, driven by the continued strong demand for the Company's Reproductive Health range of products
  - Cash position at 30 June 2025 was £23.8 million (31 December 2024: £30.5 million), and the Group remains debt free and confident that the cash runway is sufficient to reach EBITDA profitability

**Post Period Highlights**

- LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing, was successfully launched in July 2025

**Commenting Lyn Rees, Chief Executive Officer, said:** "We are pleased with the Company's performance to date, following an extensive period of restructuring and consolidation and remain focused on executing growth to see the Company through to EBITDA profitability. We are proud to announce the successful launch of LightBench® Discover, putting Novacyt at the forefront of genomic research."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

**Contacts**

**Novacyt SA**  
Lyn Rees, Chief Executive Officer  
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>  
Via Walbrook PR

**SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**  
Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

**Deutsche Numis (Joint Broker)**  
Freddie Barnfield / Duncan Monteith / Michael Palser

+44 (0)20 7260 1000

**Allegra Finance (French Listing Sponsor)**  
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10  
[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

**Walbrook PR (Financial PR & IR)**  
Paul McManus / Lianne Applegarth  
Alice Woodings

+44 (0)20 7933 8780 or [novacyt@walbrookpr.com](mailto:novacyt@walbrookpr.com)  
+44 (0)7980 541 893 / +44 (0)7584 391 303  
+44 (0)7407 804 654

**About Novacyt Group ([www.novacyt.com](http://www.novacyt.com))**

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

**Clinical** Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

**Instrumentation** Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment

- Nanogel technology, automated DNA sample preparation and target enrichment technology
- genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

**Research Use Only** Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTBRGDRRSDDGUI